Reviewing Hemispherx Biopharma Inc. (HEB)’s and Halozyme Therapeutics Inc. (NASDAQ:HALO)’s results

This is a contrast between Hemispherx Biopharma Inc. (NYSEAMERICAN:HEB) and Halozyme Therapeutics Inc. (NASDAQ:HALO) based on their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership. The two companies are Biotechnology and they also compete with each other.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Hemispherx Biopharma Inc. N/A 66.32 10.20M -0.26 0.00
Halozyme Therapeutics Inc. 281.19M 8.38 45.68M 0.27 57.91

Table 1 highlights Hemispherx Biopharma Inc. and Halozyme Therapeutics Inc.’s gross revenue, earnings per share and valuation.


Table 2 shows the return on assets, return on equity and net margins of the two firms.

Net Margins Return on Equity Return on Assets
Hemispherx Biopharma Inc. 0.00% -118.5% -66.5%
Halozyme Therapeutics Inc. 16.25% 18.9% 9.4%

Risk & Volatility

Hemispherx Biopharma Inc.’s -0.53 beta indicates that its volatility is 153.00% less volatile than that of Standard & Poor’s 500. From a competition point of view, Halozyme Therapeutics Inc. has a 1.82 beta which is 82.00% more volatile compared to Standard & Poor’s 500.


The Current Ratio of Hemispherx Biopharma Inc. is 1 while its Quick Ratio stands at 1. The Current Ratio of rival Halozyme Therapeutics Inc. is 3.1 and its Quick Ratio is has 3. Halozyme Therapeutics Inc. is better equipped to clear short and long-term obligations than Hemispherx Biopharma Inc.

Analyst Recommendations

The next table highlights the given recommendations and ratings for Hemispherx Biopharma Inc. and Halozyme Therapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Hemispherx Biopharma Inc. 0 0 0 0.00
Halozyme Therapeutics Inc. 0 0 2 3.00

Competitively the average price target of Halozyme Therapeutics Inc. is $24, which is potential 46.52% upside.

Institutional & Insider Ownership

Roughly 5% of Hemispherx Biopharma Inc. shares are held by institutional investors while 89.3% of Halozyme Therapeutics Inc. are owned by institutional investors. 2.6% are Hemispherx Biopharma Inc.’s share held by insiders. Comparatively, insiders own roughly 5% of Halozyme Therapeutics Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Hemispherx Biopharma Inc. 9.67% -10.27% -23.04% -37.92% -38.85% -42.95%
Halozyme Therapeutics Inc. -6% -2.45% -10.55% -18.01% -18.19% -23.4%

For the past year Hemispherx Biopharma Inc.’s stock price has bigger decline than Halozyme Therapeutics Inc.


Halozyme Therapeutics Inc. beats Hemispherx Biopharma Inc. on 10 of the 11 factors.

Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The companyÂ’s approved products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of sexually transmitted disease infection; and Ampligen, a product approved for sale in Argentina for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, renal cell carcinoma, and malignant melanoma; Alferon N Injection for the treatment of various categories of genital warts; and Alferon LDO, a low-dose oral liquid formulation of natural alpha interferon for the treatment of pandemic influenza, seasonal influenza, and other viruses. The company was founded in 1990 and is headquartered in Philadelphia, Pennsylvania.

Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The companyÂ’s human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. Its products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. The company offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs; in subcutaneous urography; and to enhance resorption of radiopaque agents. It also develops PEGylated recombinant human hyaluronidase for the treatment of pancreatic ductal adenocarcinoma, non-small cell lung cancer, gastric cancer, and metastatic breast cancer. It has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; and Genentech. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.